CHOP Plus Mosunetuzumab as First Line in Patients With Richters Syndrome: a Phase II Study of the Spanish Group of CLL
Status:
RECRUITING
Trial end date:
2028-05-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if drug Mosunetuzumab works to treat Richtersyndrome . It will also learn about the safety of drug Mosunetuzumab. The main questions it aims to evaluate the efficacy of mosunetuzumab combined with CHOP (M-CHOP) after the end of induction in patients with Richters Syndrome who have never received thearapy
What medical problems do participants have when taking drug Mosunetuzumab? Patients with Richters Syndrome
Participants will:
Take drug Mosunetuzumab+CHOP during 6 cycle and they if they are not candidate to Alothasplant continuing 11 cycles more with mosunetuzumab on monoterapy Visit the clinic once every 23weeks for checkups and tests
Phase:
PHASE2
Details
Lead Sponsor:
GELLC (Grupo Espaol de Leucemia Linfoctica Crnica)